GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Forward Rate of Return (Yacktman) %

Allena Pharmaceuticals (Allena Pharmaceuticals) Forward Rate of Return (Yacktman) % : 0.00% (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Allena Pharmaceuticals's forward rate of return for was 0.00%.

The historical rank and industry rank for Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % or its related term are showing as below:

ALNAQ's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.77
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Allena Pharmaceuticals Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals Forward Rate of Return (Yacktman) % Chart

Allena Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial - - - - -

Allena Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allena Pharmaceuticals's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Allena Pharmaceuticals's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % falls into.



Allena Pharmaceuticals Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Allena Pharmaceuticals's Forward Rate of Return of Jun. 2022 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.191+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allena Pharmaceuticals  (OTCPK:ALNAQ) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Allena Pharmaceuticals Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
Louis Md Brenner officer: See Remarks RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick director 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz officer: Chief Financial Officer 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan officer: Chief Financial Officer C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p. 10 percent owner C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp 10 percent owner 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper director, 10 percent owner 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin director, officer: Chief Executive Officer C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139

Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines

From GuruFocus